CHEMISTRY LETTERS

Scope & Guideline

Innovative insights for the chemistry community.

Introduction

Delve into the academic richness of CHEMISTRY LETTERS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0366-7022
PublisherCHEMICAL SOC JAPAN
Support Open AccessNo
CountryJapan
TypeJournal
Converge1973, 1979, 1981, 1988, from 1996 to 2024
AbbreviationCHEM LETT / Chem. Lett.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1-5 KANDA-SURUGADAI CHIYODA-KU, TOKYO 101-8307, JAPAN

Aims and Scopes

CHEMISTRY LETTERS focuses on a broad spectrum of research in medicinal chemistry, emphasizing innovative approaches to drug discovery and development. The journal seeks to publish high-quality research that contributes to the understanding of molecular interactions, the design of novel therapeutic agents, and the application of cutting-edge technologies in drug discovery.
  1. Medicinal Chemistry and Drug Discovery:
    The core focus of the journal is on medicinal chemistry, with an emphasis on the design, synthesis, and evaluation of new drug candidates across various therapeutic areas.
  2. Structure-Activity Relationship Studies:
    Research articles often explore the relationship between chemical structure and biological activity, providing insights into optimizing lead compounds for better efficacy and selectivity.
  3. Innovative Synthetic Methods:
    The journal publishes studies that introduce novel synthetic methodologies, which are crucial for the development of complex drug molecules.
  4. Biological Evaluation:
    A significant aspect of the published works involves the biological evaluation of new compounds, including in vitro and in vivo studies that assess pharmacological effects and mechanisms of action.
  5. Emerging Technologies in Drug Development:
    The integration of advanced technologies such as artificial intelligence, machine learning, and high-throughput screening is a consistent theme, reflecting the journal's commitment to modernizing drug discovery processes.
Recent publications in CHEMISTRY LETTERS indicate several emerging trends and themes that reflect the evolving landscape of medicinal chemistry and drug discovery. These trends highlight areas of growing interest and potential future research directions.
  1. Targeted Protein Degradation (TPD):
    There is a significant increase in studies focusing on targeted protein degradation technologies, such as PROTACs, which are gaining traction as a novel therapeutic strategy to tackle previously 'undruggable' targets.
  2. AI and Machine Learning Applications:
    The application of artificial intelligence and machine learning in drug discovery is on the rise, with more studies exploring how these technologies can enhance predictive modeling and optimize lead compounds.
  3. Novel Therapeutic Modalities:
    Emerging themes include the development of innovative therapeutic modalities, such as bispecific antibodies, gene editing technologies, and advanced nanomedicine approaches for targeted delivery.
  4. Immunotherapy and Cancer Treatment:
    Research related to immunotherapy, particularly the development of immune checkpoint inhibitors and CAR T-cell therapies, is increasingly prominent, reflecting the ongoing revolution in cancer treatment.
  5. Neuropharmacology and CNS Disorders:
    There is a growing emphasis on neuropharmacology, with increased research into compounds targeting neurological disorders, reflecting the pressing need for effective treatments in this area.

Declining or Waning

While CHEMISTRY LETTERS continues to publish a wide array of topics in medicinal chemistry, certain areas have shown a decline in publication frequency or emphasis over time. This section highlights these waning themes to inform researchers of shifting academic interests and funding priorities.
  1. Traditional Natural Product Chemistry:
    There has been a noticeable decrease in publications focused on traditional natural product chemistry, as the field shifts towards more synthetic and combinatorial approaches to drug discovery.
  2. Basic Pharmacological Studies:
    Research that primarily emphasizes basic pharmacological studies without a clear application to drug discovery or development is becoming less prevalent, as the journal favors studies with translational relevance.
  3. Non-Covalent Drug Interactions:
    The exploration of non-covalent drug interactions appears to be waning, with a shift towards studies that investigate covalent inhibitors and their mechanisms of action.

Similar Journals

Anti-Cancer Agents in Medicinal Chemistry

Empowering researchers with cutting-edge insights in oncology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

PHARMACEUTICAL CHEMISTRY JOURNAL

Shaping the Future of Pharmaceutical Research.
Publisher: SPRINGERISSN: 0091-150XFrequency: 12 issues/year

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

MOLECULAR DIVERSITY

Advancing Interdisciplinary Research in Chemistry and Biology
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

TETRAHEDRON

Transforming ideas into impactful scientific discoveries.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0040-4020Frequency: 52 issues/year

TETRAHEDRON, published by Pergamon-Elsevier Science Ltd, is a leading peer-reviewed journal that has been pivotal in advancing the fields of Biochemistry, Drug Discovery, and Organic Chemistry since its inception in 1957. With an ISSN of 0040-4020 and an E-ISSN of 1464-5416, this journal provides a platform for the dissemination of cutting-edge research and innovative methodologies that contribute significantly to the scientific community. Recognized for its rigorous editorial standards, TETRAHEDRON has been categorized in the Q3 quartile for 2023 across its relevant fields, reflecting its solid impact within the scientific sphere. Despite the current absence of Open Access options, the journal continues to engage a diverse readership, offering invaluable insights and advancements that fuel both academic and industrial applications. With an ongoing commitment to excellence, TETRAHEDRON remains an essential resource for researchers, professionals, and students aiming to stay at the forefront of chemistry and biochemistry research.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Fostering Knowledge Exchange for Future Medical Breakthroughs.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Chemical Biology & Drug Design

Transforming research into real-world health solutions.
Publisher: WILEYISSN: 1747-0277Frequency: 12 issues/year

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

CURRENT MEDICINAL CHEMISTRY

Shaping Tomorrow’s Medicines Through Rigorous Research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

HETEROATOM CHEMISTRY

Transforming Research: The Essence of Heteroatom Chemistry
Publisher: WILEY-HINDAWIISSN: 1042-7163Frequency: 1 issue/year

Heteroatom Chemistry is a prominent open-access journal dedicated to advancing the field of heteroatom chemistry, with a particular focus on the chemistry of elements other than carbon in organic compounds. Published by Wiley-Hindawi, this journal provides researchers, professionals, and students with a platform to disseminate and access novel research findings related to the synthesis, properties, and applications of heteroatom-containing compounds. Since its inception in 1990 and gaining open access status in 2019, the journal has fostered academic collaboration and innovation throughout its converged years, although it currently holds a category quartile ranking of Q4 in Chemistry (miscellaneous) and ranks #319 out of 408 in general chemistry within Scopus. With its commitment to high-quality research and broad accessibility, Heteroatom Chemistry is poised to be an essential resource for anyone looking to explore the rich and varied applications of heteroatom chemistry in diverse scientific fields.

Medicinal Chemistry

Transforming drug development with insightful findings.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4064Frequency: 8 issues/year

Medicinal Chemistry is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of drug discovery and development. Established in 2005 with a converged publication timeframe extending to 2024, this journal serves as a vital resource for researchers and professionals interested in the intricate processes of medicinal chemistry, pharmacology, and toxicology. With an ISSN of 1573-4064 and an E-ISSN of 1875-6638, it has established a notable presence in the academic community, currently positioned in Q3 of Drug Discovery category according to the 2023 quartiles. The journal's ranking in Scopus places it at 90 out of 157 in its field, showcasing its impact and relevance, with a percentile standing of 42. Although the journal is not open access, it continues to provide insightful articles and research findings that contribute significantly to the understanding and innovation in medicinal chemistry. Based in the United Arab Emirates, Medicinal Chemistry is committed to disseminating high-quality research that shapes the future of drug formulation and therapeutic advancement.

ChemMedChem

Advancing the frontiers of medicinal chemistry.
Publisher: WILEY-V C H VERLAG GMBHISSN: 1860-7179Frequency: 24 issues/year

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.